|
|
||||||||

* Department of Immunochemistry and Biochemical Microbiology, Division of Biophysics, Leibniz-Center for Medicine and Biosciences, Research Center Borstel, Borstel, Germany; and
XOMA (US) LLC, Berkeley, CA 94710
The inhibition of LPS-induced cell activation by specific antagonists is a long-known phenomenon; however, the underlying mechanisms are still poorly understood. It is commonly accepted that the membrane-bound receptors mCD14 and TLR4 are involved in the activation of mononuclear cells by LPS and that activation may be enhanced by soluble LPS-binding protein (LBP). Hexaacylated Escherichia coli lipid A has the highest cytokine-inducing capacity, whereas lipid A with four fatty acids (precursor IVa, synthetic compound 406) is endotoxically inactive, but expresses antagonistic activity against active LPS. Seeking to unravel basic molecular principles underlying antagonism, we investigated phospholipids with structural similarity to compound 406 with respect to their antagonistic activity. The tetraacylated diphosphatidylglycerol (cardiolipin, CL) exhibits high structural similarity to 406, and our experiments showed that CL strongly inhibited LPS-induced TNF-
release when added to the cells before stimulation or as a CL/LPS mixture. Also negatively charged and to a lesser degree zwitterionic diacyl phospholipids inhibited LPS-induced cytokine production. Using Abs against LBP, we could show that the activation of cells by LPS was dependent on the presence of cell-associated LBP, thus making LBP a possible target for the antagonistic action of phospholipids. In experiments investigating the LBP-mediated intercalation of LPS and phospholipids into phospholipid liposomes mimicking the macrophage membrane, we could show that preincubation of soluble LBP with phospholipids leads to a significant reduction of LPS intercalation. In summary, we show that LBP is a target for the inhibitory function of phospholipids.
This article has been cited by other articles:
![]() |
P. Sheth, N. Delos Santos, A. Seth, N. F. LaRusso, and R. K. Rao Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G308 - G318. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Dallard, V. Ruffino, S. Heffel, and L. F. Calvinho Effect of a Biological Response Modifier on Expression of Growth Factors and Cellular Proliferation at Drying Off J Dairy Sci, May 1, 2007; 90(5): 2229 - 2240. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Schromm, J. Howe, A. J. Ulmer, K.-H. Wiesmuller, T. Seyberth, G. Jung, M. Rossle, M. H. J. Koch, T. Gutsmann, and K. Brandenburg Physicochemical and Biological Analysis of Synthetic Bacterial Lipopeptides: VALIDITY OF THE CONCEPT OF ENDOTOXIC CONFORMATION J. Biol. Chem., April 13, 2007; 282(15): 11030 - 11037. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mueller, C. Stamme, C. Draing, T. Hartung, U. Seydel, and A. B. Schromm Cell Activation of Human Macrophages by Lipoteichoic Acid Is Strongly Attenuated by Lipopolysaccharide-binding Protein J. Biol. Chem., October 20, 2006; 281(42): 31448 - 31456. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Papavlassopoulos, C. Stamme, L. Thon, D. Adam, D. Hillemann, U. Seydel, and A. B. Schromm MaxiK Blockade Selectively Inhibits the Lipopolysaccharide-Induced I{kappa}B-{alpha}/NF-{kappa}B Signaling Pathway in Macrophages J. Immunol., September 15, 2006; 177(6): 4086 - 4093. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mueller, B. Lindner, R. Dedrick, A.B. Schromm, and U. Seydel Endotoxin: physical requirements for cell activation Innate Immunity, October 1, 2005; 11(5): 299 - 303. [Abstract] [PDF] |
||||
![]() |
N. W.J. Schroder and R. R. Schumann Non-LPS targets and actions of LPS binding protein (LBP) Innate Immunity, August 1, 2005; 11(4): 237 - 242. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |